Senolytics by Age Group: When to Start and How to Adjust Dosing
Expert Summary
Senescent cells are present even in young adults (~1–2% in some tissues) but accumulate exponentially from age 40. The senescent cell burden approximately doubles every decade from 40 to 80, with an inflection point at ~60 where accumulation accelerates. Senolytic protocols should scale accordingly.
Key Facts
- Under 40: Senescent cells are present but low burden. Spermidine (daily, 1–2 mg) + quercetin (200 mg/day) as preventive maintenance. Quarterly fisetin burst optional from late 30s.
- 40–49: Accumulation beginning to accelerate. Start quarterly fisetin (20 mg/kg × 2 days) + quercetin phytosome (200–300 mg/day). Consider blood biomarker tracking (hsCRP, IL-6) to establish baseline.
- 50–59: Accumulation rate increasing significantly. Transition to bimonthly or monthly fisetin cycling. Add spermidine (2–3 mg/day). Consider first longevity physician consultation re: D+Q eligibility.
- 60–69: Monthly senolytic cycling recommended. Full natural stack: fisetin (monthly) + quercetin phytosome (200 mg/day + 1,000 mg on burst days) + spermidine (3–4 mg/day) + NMN (250–500 mg/day). Discuss D+Q with physician.
- 70+: Monthly senolytics + physician-supervised D+Q (quarterly). Prioritize functional outcomes: gait speed, grip strength, stair climbing. Frailty prevention is the primary clinical goal.
- Biomarker-guided escalation: At any age, elevated hsCRP (>3 mg/L) or IL-6 (>2.5 pg/mL) suggests higher senescent cell burden and warrants more aggressive cycling frequency.
Recommended Products
Frequently Asked Questions
Is there such a thing as starting senolytics too early?
Quarterly natural senolytics (fisetin, quercetin) have an excellent safety record and no documented risks of starting early. Some longevity researchers suggest beginning in one's 30s for prevention, though evidence for benefits at this age is speculative.
Should I stop senolytics at a certain age?
No upper age limit has been established. Frailty trials enrolled participants up to age 85+. The risk-benefit calculation may change in the very elderly (85+) where physician oversight becomes more important.
Scientific References
- Sharpless NE et al. How the cell cycle controls cellular aging. Aging Cell. 2021. PMID: 27503792
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis. EBioMedicine. 2019. PMID: 30616998